Foundational IP for Higher-Value Genomic Interpretation

This portfolio represents a foundational intellectual property platform designed to advance precision oncology, cancer diagnostics, and AI-enabled genomic analysis. Built around patented codon-context causal mutagenesis technology, the portfolio identifies the biological mechanisms responsible for DNA mutations, providing a mechanistic layer of genomic interpretation that extends beyond conventional statistical biomarkers. By attributing mutations to specific deaminase enzymes, including APOBEC and AID, the technology enables more informed clinical decision-making and supports the development of next-generation companion diagnostics.

The portfolio is supported by an operational technology platform that combines proprietary AI and machine learning pipelines, the Codon Reference Information System (CRIS), and a curated scientific reference database. Together, these capabilities enable comprehensive genomic analysis and seamless integration into existing sequencing workflows, molecular diagnostics, pharmaceutical research, and precision medicine applications. This combination of patented technology and deployable infrastructure offers strategic value for organizations seeking to accelerate innovation in oncology and genomic medicine.

The technology has been evaluated through multiple independent validation studies and commercial datasets, demonstrating strong performance in identifying patients who are unlikely to benefit from immune checkpoint inhibitor therapies. These capabilities support improved patient stratification, treatment selection, longitudinal disease monitoring, cancer recurrence assessment, and biomarker discovery, helping address one of the most significant clinical and economic challenges in modern cancer care.

Potential commercial applications include precision oncology, immunotherapy response prediction, companion diagnostics, liquid biopsy, minimal residual disease monitoring, genomic sequencing, AI-driven cancer diagnostics, pharmaceutical clinical trial enrichment, and deaminase-targeted drug development. This portfolio presents an attractive acquisition or licensing opportunity for biotechnology companies, pharmaceutical organizations, molecular diagnostics developers, genomic sequencing providers, and AI healthcare innovators seeking foundational intellectual property that can enhance cancer diagnostics, therapeutic development, and precision medicine solutions.